NCT03924895 | Cancer Search

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

A global, randomized phase III study to evaluate perioperative pembrolizumab with radical cystectomy + pelvic lymph node dissection (RC+PLND) versus RC+PLND alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

phase

Phase 3

status

Recruiting

enrollment

836

score

start date

2019-07-24

last updated

2022-01-17

biomarkers

N/A

conditions

Bladder Urothelial Carcinoma

drugs

cystectomy

enfortumab vedotin

pembrolizumab

primary contact

Toll Free Number

source

clinicaltrials.gov

New York City, New York

Icahn School of Medicine at Mount Sinai ( Site 0031)

Chicago, Illinois

John H. Stroger Jr. Hospital of Cook County ( Site 1551)

University of Chicago ( Site 0068)

Indianapolis, Indiana

Indiana University Melvin and Bren Simon Comprehensive Cancer Center ( Site 0004)

Washington, Washington, D.C.

Georgetown University Medical Center ( Site 0022)

Nashville, Tennessee

Urology Associates [Nashville, TN] ( Site 0053)

Atlanta, Georgia

Emory School of Medicine ( Site 0006)

Cleveland, Ohio

Cleveland Clinic ( Site 1576)

Aurora, Colorado

University of Colorado Hospital ( Site 0098)

Fort Wayne, Indiana

Parkview Cancer Institute ( Site 0077)

Mobile, Alabama

University of South Alabama, Mitchell Cancer Institute ( Site 1582)

Fullerton, California

St. Joseph Heritage Healthcare ( Site 0046)

Myrtle Beach, South Carolina

Carolina Urologic Research Center ( Site 0062)

87 sites
Page 1 of 8

Open Page 2